カテゴリー： Transparency Market Research, 世界, 医療/バイオ

世界の希少腎臓疾患治療市場2022年ｰ2031年：薬効クラス別（酵素補充療法、モノクローナル抗体、その他）

◆英語タイトル：Rare Kidney Diseases Treatment Market (Drug Class: Enzyme Replacement Therapy, Monoclonal Antibodies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
	◆商品コード：TMR23JA089 ◆発行会社（リサーチ会社）：Transparency Market Research ◆発行日：2022年11月30日 ◆ページ数：186 ◆レポート形式：英語 / PDF ◆納品方法：Eメール（受注後24時間以内） ◆調査対象地域：グローバル ◆産業分野：医薬品

◆販売価格オプション（消費税別）

Single User（1名様閲覧）	USD5,795 ⇒換算￥869,250	見積依頼/購入/質問フォーム
Multi User（5名様閲覧）	USD8,795 ⇒換算￥1,319,250	見積依頼/購入/質問フォーム
Corporate License（法人閲覧）	USD11,795 ⇒換算￥1,769,250	見積依頼/購入/質問フォーム

★Transparency Market Researchに受託調査の見積を依頼する

※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Transparency Market Research社は、世界の希少腎臓疾患治療市場について調査し、序論、仮定・調査手法、市場概要、主要インサイト、疾患別（ファブリー病、非定型溶血性尿毒症症候群、ループス腎炎、腎症性シスチン症、その他）分析、薬効クラス別（酵素補充療法、モノクローナル抗体、その他）分析、流通チャネル別（病院薬局、小売薬局、オンライン薬局）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況、企業情報などの内容を掲載しています。なお、当書に掲載されている企業情報には、Calliditas Therapeutics AB、GSK plc、Aurinia Pharmaceuticals, Inc.、Amicus Therapeutics, Inc.、Shire (Takeda Pharmaceutical Company Limited)、Sanofi、Advicenne、Alexion Pharmaceuticals, Inc.、Horizon Therapeutics plc、Otsuka Pharmaceutical Co., Ltd.などが含まれています。
・序論
・仮定・調査手法
・市場概要
・主要インサイト

・世界の希少腎臓疾患治療市場規模：疾患別
- ファブリー病の市場規模
- 非定型溶血性尿毒症症候群の市場規模
- ループス腎炎の市場規模
- 腎症性シスチン症の市場規模
- その他疾患の市場規模

・世界の希少腎臓疾患治療市場規模：薬効クラス別
- 酵素補充療法の市場規模
- モノクローナル抗体の市場規模
- その他薬効クラスの市場規模

・世界の希少腎臓疾患治療市場規模：流通チャネル別
- 病院薬局の市場規模
- 小売薬局の市場規模
- オンライン薬局の市場規模

・世界の希少腎臓疾患治療市場規模：地域別
- 北米の希少腎臓疾患治療市場規模
- ヨーロッパの希少腎臓疾患治療市場規模
- アジア太平洋の希少腎臓疾患治療市場規模
- 中南米の希少腎臓疾患治療市場規模
- 中東/アフリカの希少腎臓疾患治療市場規模

・競争状況
・企業情報

Rare Kidney Diseases Treatment Market – Scope of Report
TMR’s report on the global rare kidney diseases treatment market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global rare kidney diseases treatment market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global rare kidney diseases treatment market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the rare kidney diseases treatment market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global rare kidney diseases treatment market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global rare kidney diseases treatment market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global rare kidney diseases treatment market.

The report delves into the competitive landscape of the global rare kidney diseases treatment market. Key players operating in the global rare kidney diseases treatment market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global rare kidney diseases treatment market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market rare kidney diseases treatment.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

❖ レポートの目次 ❖

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Rare Kidney Diseases Treatment Market
4. Market Overview
4.1. Introduction
4.1.1. Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Disease Epidemiology
5.3. Key Industry Events
5.4. COVID-19 Impact Analysis
6. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Indication
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Indication, 2017–2031
6.3.1. Fabry Disease
6.3.2. Atypical Hemolytic Uremic Syndrome
6.3.3. Lupus Nephritis
6.3.4. Nephropathic Cystinosis
6.3.5. Others
6.4. Market Attractiveness Analysis, by Indication
7. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Drug Class
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Drug Class, 2017–2031
7.3.1. Enzyme Replacement Therapy
7.3.2. Monoclonal Antibodies
7.3.3. Others
7.4. Market Attractiveness Analysis, by Drug Class
8. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Sales
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Rare Kidney Diseases Treatment Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Rare Kidney Diseases Treatment Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Indication, 2017–2031
10.2.1. Fabry Disease
10.2.2. Atypical Hemolytic Uremic Syndrome
10.2.3. Lupus Nephritis
10.2.4. Nephropathic Cystinosis
10.2.5. Others
10.3. Market Value Forecast, by Drug Class, 2017–2031
10.3.1. Enzyme Replacement Therapy
10.3.2. Monoclonal Antibodies
10.3.3. Others
10.4. Market Value Forecast, by Distribution Channel, 2017–2031
10.4.1. Hospital Pharmacies
10.4.2. Retail Pharmacies
10.4.3. Online Sales
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Indication
10.6.2. By Drug Class
10.6.3. By Distribution Channel
10.6.4. By Country
11. Europe Rare Kidney Diseases Treatment Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Indication, 2017–2031
11.2.1. Fabry Disease
11.2.2. Atypical Hemolytic Uremic Syndrome
11.2.3. Lupus Nephritis
11.2.4. Nephropathic Cystinosis
11.2.5. Others
11.3. Market Value Forecast, by Drug Class, 2017–2031
11.3.1. Enzyme Replacement Therapy
11.3.2. Monoclonal Antibodies
11.3.3. Others
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Sales
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Indication
11.6.2. By Drug Class
11.6.3. By Distribution Channel
11.6.4. By Country/Sub-region
12. Asia Pacific Rare Kidney Diseases Treatment Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Indication, 2017–2031
12.2.1. Fabry Disease
12.2.2. Atypical Hemolytic Uremic Syndrome
12.2.3. Lupus Nephritis
12.2.4. Nephropathic Cystinosis
12.2.5. Others
12.3. Market Value Forecast, by Drug Class, 2017–2031
12.3.1. Enzyme Replacement Therapy
12.3.2. Monoclonal Antibodies
12.3.3. Others
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Sales
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Indication
12.6.2. By Drug Class
12.6.3. By Distribution Channel
12.6.4. By Country/Sub-region
13. Latin America Rare Kidney Diseases Treatment Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Indication, 2017–2031
13.2.1. Fabry Disease
13.2.2. Atypical Hemolytic Uremic Syndrome
13.2.3. Lupus Nephritis
13.2.4. Nephropathic Cystinosis
13.2.5. Others
13.3. Market Value Forecast, by Drug Class, 2017–2031
13.3.1. Enzyme Replacement Therapy
13.3.2. Monoclonal Antibodies
13.3.3. Others
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Sales
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Indication
13.6.2. By Drug Class
13.6.3. By Distribution Channel
13.6.4. By Country/Sub-region
14. Middle East & Africa Rare Kidney Diseases Treatment Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Indication, 2017–2031
14.2.1. Fabry Disease
14.2.2. Atypical Hemolytic Uremic Syndrome
14.2.3. Lupus Nephritis
14.2.4. Nephropathic Cystinosis
14.2.5. Others
14.3. Market Value Forecast, by Drug Class, 2017–2031
14.3.1. Enzyme Replacement Therapy
14.3.2. Monoclonal Antibodies
14.3.3. Others
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Sales
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Indication
14.6.2. By Drug Class
14.6.3. By Distribution Channel
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Calliditas Therapeutics AB
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Overview
15.3.1.3. Financial Overview
15.3.1.4. Strategy Overview
15.3.1.5. SWOT Analysis
15.3.2. GSK plc
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Overview
15.3.2.3. Financial Overview
15.3.2.4. Strategy Overview
15.3.2.5. SWOT Analysis
15.3.3. Aurinia Pharmaceuticals, Inc.
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Overview
15.3.3.3. Financial Overview
15.3.3.4. Strategy Overview
15.3.3.5. SWOT Analysis
15.3.4. Amicus Therapeutics, Inc.
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Overview
15.3.4.3. Financial Overview
15.3.4.4. Strategy Overview
15.3.4.5. SWOT Analysis
15.3.5. Shire (Takeda Pharmaceutical Company Limited)
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Overview
15.3.5.3. Financial Overview
15.3.5.4. Strategy Overview
15.3.5.5. SWOT Analysis
15.3.6. Sanofi
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Overview
15.3.6.3. Financial Overview
15.3.6.4. Strategy Overview
15.3.6.5. SWOT Analysis
15.3.7. Advicenne
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Overview
15.3.7.3. Financial Overview
15.3.7.4. Strategy Overview
15.3.7.5. SWOT Analysis
15.3.8. Alexion Pharmaceuticals, Inc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Overview
15.3.8.3. Financial Overview
15.3.8.4. Strategy Overview
15.3.8.5. SWOT Analysis
15.3.9. Horizon Therapeutics plc
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Overview
15.3.9.3. Financial Overview
15.3.9.4. Strategy Overview
15.3.9.5. SWOT Analysis
15.3.10. Otsuka Pharmaceutical Co., Ltd.
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Overview
15.3.10.3. Financial Overview
15.3.10.4. Strategy Overview
15.3.10.5. SWOT Analysis
15.3.11. Reata Pharmaceuticals, Inc.
15.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.11.2. Product Overview
15.3.11.3. Financial Overview
15.3.11.4. Strategy Overview
15.3.11.5. SWOT Analysis

❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の希少腎臓疾患治療市場2022年ｰ2031年：薬効クラス別（酵素補充療法、モノクローナル抗体、その他）(Rare Kidney Diseases Treatment Market (Drug Class: Enzyme Replacement Therapy, Monoclonal Antibodies, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031)]についてメールでお問い合わせはこちらでお願いします。

GlobalResearch.jp

世界の希少腎臓疾患治療市場2022年ｰ2031年：薬効クラス別（酵素補充療法、モノクローナル抗体、その他）

グローバル市場調査/マーケットリサーチ会社：レポート販売と委託調査サービス提供 www.GlobalResearch.jp